Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2024, Mr. Omar Jimenez, the Chief Financial Officer (principal financial/accounting officer) and Secretary of 180 Life Sciences Corp. (the "Company ", "we" and "us"), tendered his resignation to the board of directors of the Company (the "Board"), effective immediately. Mr. Jimenez's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

As a result of Mr. Jimenez's resignation, current Interim Chief Executive Officer, Blair Jordan, assumed the role of principal financial/accounting officer of the Company, effective as of the date of Mr. Jimenez's resignation, on an interim basis, until such time as a replacement is named. Biographical and other information regarding Mr. Jordan is set forth in the Company's proxy statement, filed with the Securities and Exchange Commission on November 12, 2024, under the section "Information About Our Executive Officers and Directors-Director Nominees", and such information is incorporated by reference herein. There are no arrangements or understandings between Mr. Jordan and any other person requiring disclosure under Item 401(b) of Regulation S-K and no transactions with related persons requiring disclosure under Item 404(a) of Regulation S-K, except as disclosed in the proxy statement. Mr. Jordan will not receive any additional compensation in connection with assuming the responsibilities of the principal accounting/financial officer of the Company on an interim basis.